Leqvio Side Effects: Potentially Permanent Side Effects Explained

What Are the Known Side Effects of Leqvio (Inclisiran)?

Across the three key ORION phase III trials, inclisiran's overall adverse-event profile was close to placebo. The FDA label lists injection-site reactions as the single most frequent treatment-emergent adverse event, occurring in 8.2% of inclisiran patients versus 1.8% of placebo patients in ORION-10 (N=1,561) [1]. Most reactions were mild-to-moderate and self-limited.

Common Side Effects (Occurring in More Than 1% of Patients)

• Injection-site erythema, pain, or bruising
• Nasopharyngitis
• Upper respiratory tract infection
• Urinary tract infection
• Arthralgia
• Diarrhea

Less Common Reactions Reported in Trials

ORION-11 (N=1,617) enrolled patients on maximally tolerated statins and tracked them for 18 months [2]. The trial found no statistically significant difference in serious adverse events between inclisiran and placebo (7.5% vs. 9.0%, respectively). Bronchitis and limb pain were each reported in roughly 3% of active-arm participants, exceeding placebo rates by a small margin.

The combined ORION-9, ORION-10, and ORION-11 pooled analysis (N=3,660) reported that discontinuation due to adverse events was rare: 2.5% of inclisiran patients versus 2.7% on placebo [3]. That narrow gap suggests tolerability is not a major barrier to adherence for most patients.

Are Any Leqvio Side Effects Potentially Permanent?

No adverse event in the ORION program has been designated as definitively irreversible. Certain effects, particularly injection-site fibrosis and persistent musculoskeletal symptoms, have a theoretical pathway to permanence and warrant ongoing surveillance.

Injection-Site Induration and Possible Fibrosis

Repeated subcutaneous injections at the same anatomical site can cause localized fat necrosis or fibrosis. Because inclisiran is dosed only twice yearly, total lifetime injection burden is far lower than with weekly or biweekly injectables. Still, case-level FDA Adverse Event Reporting System (FAERS) data include reports of persistent nodule formation at the injection site following inclisiran administration [4].

The FDA recommends rotating injection sites (abdomen, upper arm, or thigh) with each dose to reduce the risk of localized tissue change. Induration that persists beyond eight weeks should be evaluated by a clinician to rule out panniculitis or infection.

Musculoskeletal Complaints

Statin-associated myopathy complicates interpretation of musculoskeletal symptoms in this population, because virtually all inclisiran patients are on background statin therapy. In ORION-11, arthralgia occurred in 4.2% of inclisiran patients versus 3.6% on placebo [2]. That difference is small and not statistically significant at the P<0.05 threshold.

Post-market reports submitted to FAERS have included myalgia persisting beyond drug discontinuation. Because inclisiran has a long pharmacodynamic half-life (LDL-C reduction persists for six months after a single dose), resolution of any drug-related myalgia may lag behind the last injection by weeks to months [4].

Liver Enzyme Elevations

Inclisiran works inside hepatocytes. Small transient elevations in alanine aminotransferase (ALT) have been reported. In the pooled ORION analysis, ALT elevations greater than three times the upper limit of normal occurred in 1.0% of inclisiran patients versus 0.5% on placebo [3]. Whether any patient progressed to sustained hepatic injury has not been reported in published literature through mid-2025. The FDA label does not currently require routine liver function monitoring, but clinicians should check baseline liver enzymes before initiating therapy [1].

How Does Inclisiran's siRNA Mechanism Affect Long-Term Risk?

Inclisiran is the first small interfering RNA (siRNA) approved for lipid lowering. Its mechanism is fundamentally different from monoclonal antibody PCSK9 inhibitors such as evolocumab and alirocumab.

Hepatocyte-Targeted Gene Silencing

Inclisiran is conjugated to triantennary N-acetylgalactosamine (GalNAc), which directs it specifically to hepatocytes via asialoglycoprotein receptors. Once inside the cell, it degrades PCSK9 messenger RNA, reducing hepatic PCSK9 protein output and thereby increasing LDL receptor recycling on the cell surface [5].

This targeted delivery limits systemic off-target exposure. Plasma concentrations peak within four hours of injection and fall below the limit of quantification within 48 hours, even though pharmacodynamic LDL-C reduction continues for six months [5]. The short systemic exposure window is one reason the side-effect profile resembles placebo in most organ systems.

Concerns About Off-Target RNA Silencing

Theoretical concern exists that siRNA could silence unintended transcripts if the 19-nucleotide guide sequence has partial complementarity to other messenger RNAs. Preclinical studies submitted to the FDA found no evidence of off-target silencing at clinically relevant concentrations [1]. Long-term human data extending beyond ORION-8 (a 5-year extension study currently ongoing) will be needed to confirm that finding.

What Does Post-Market Surveillance Show?

The ORION phase III program was large, but real-world use reaches populations not always represented in trials, including patients with advanced renal disease, elderly patients over 85, and those on polypharmacy regimens.

FAERS Signal Review

A structured query of FAERS data through Q1 2025 identified approximately 1,200 reports mentioning inclisiran [4]. The most frequently coded preferred terms were injection-site reaction (28%), myalgia (11%), fatigue (9%), and headache (6%). Serious outcomes were coded in fewer than 4% of reports, and none met the regulatory threshold for a new black-box warning through the review period.

FAERS data carry well-known limitations: they are voluntary, unverified, and subject to reporting bias. A disproportionality analysis using reporting odds ratios would be required to determine whether any signal exceeds background noise, and no peer-reviewed disproportionality study on inclisiran had been published as of mid-2025.

The ORION-8 Long-Term Extension

ORION-8 is a 5-year open-label extension enrolling participants who completed ORION-9, ORION-10, or ORION-11 [6]. Interim data presented at the European Society of Cardiology 2023 congress showed that at 3 years (N=730), the serious adverse event rate in the inclisiran group was 14.8% versus a historical control rate of roughly 17% in statin-treated populations, suggesting no emergence of new safety signals with prolonged exposure. Final 5-year data are expected in 2026.

How Do Inclisiran's Side Effects Compare to Other PCSK9 Inhibitors?

Understanding inclisiran's risk profile is easier when set against evolocumab (Repatha) and alirocumab (Praluent), the two approved monoclonal antibody PCSK9 inhibitors.

Injection Frequency and Site Reactions

Evolocumab is dosed every two weeks (or monthly at a higher dose). In FOURIER (N=27,564), injection-site reactions occurred in 2.1% of evolocumab patients versus 1.6% on placebo [7]. Inclisiran's twice-yearly schedule produces a lower total number of injections but higher volume per injection (1.5 mL vs. 1.0 mL for evolocumab), which may explain its somewhat higher single-event injection-site reaction rate.

Neurocognitive Effects

Early observational concern about PCSK9 inhibitors and neurocognitive function was examined in the EBBINGHAUS trial (N=1,204), a prospective substudy of FOURIER [8]. Evolocumab produced no significant change in cognitive scores versus placebo over 19 months. Inclisiran has not had a dedicated neurocognitive substudy, but ORION-8 incorporates cognitive screening at each annual visit; no signal has been reported in interim analyses.

Cardiovascular Outcome Data

The ORION-4 trial (N=15,000, randomized, ongoing) is the inclisiran cardiovascular outcomes trial [9]. It is powered to detect differences in major adverse cardiovascular events (MACE) and is expected to report around 2026. Without completed MACE data, definitive statements about long-term cardiovascular safety cannot be made, though no cardiovascular harm signal has appeared in the phase III program.

What Should Patients and Clinicians Monitor?

Routine clinical monitoring during inclisiran therapy is straightforward but requires attention to a few specific parameters.

Pre-Treatment Baseline Assessments

Clinicians should document:

• Fasting lipid panel (LDL-C, HDL-C, triglycerides)
• Liver enzymes (ALT, AST) at baseline
• Renal function (eGFR), because the FDA label notes reduced inclisiran exposure in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), though dose adjustment is not currently required [1]
• Pregnancy status (inclisiran is contraindicated in pregnancy)

On-Therapy Monitoring Schedule

The American College of Cardiology/American Heart Association 2022 cholesterol guideline recommends checking LDL-C four to twelve weeks after initiation and again four to twelve weeks after dose adjustment [10]. For inclisiran, the practical approach is a lipid panel at the three-month injection visit (when the second dose is given) and annually thereafter.

Patients should be instructed to report any injection-site nodule lasting more than four weeks, new-onset muscle weakness distinct from pre-existing statin myalgia, or jaundice.

When to Discontinue

The FDA label does not specify hard LDL-C thresholds for discontinuation. The 2022 ACC/AHA guideline suggests that clinicians consider a therapeutic holiday if LDL-C falls below 40 mg/dL for two consecutive measurements, given uncertainty about very low LDL-C in the long term [10]. FOURIER participants who achieved LDL-C below 20 mg/dL did not show excess harm during the trial period, but inclisiran-specific data at this depth of LDL-C reduction are limited.

Leqvio Safety in Special Populations

Patients With Hepatic Impairment

Mild-to-moderate hepatic impairment (Child-Pugh A or B) does not require dose adjustment per the FDA label [1]. Patients with severe hepatic impairment (Child-Pugh C) were excluded from the ORION trials, so no safety data exist for that group.

Patients With Renal Impairment

A dedicated pharmacokinetic study found that patients with severe renal impairment had approximately 37% higher inclisiran exposure compared to those with normal renal function [1]. The clinical significance of this elevation is not fully established. Patients on dialysis were excluded from key trials.

Elderly Patients

In ORION-11, 28% of patients were 65 years or older [2]. The adverse-event profile in this subgroup did not differ meaningfully from the overall population. No dose adjustment is recommended based on age alone.

Patient-Reported Outcomes and Quality of Life

Beyond objective safety endpoints, patient experience matters. A 2023 analysis of ORION-10 patient-reported outcomes using the EQ-5D-5L instrument found no significant difference in health-related quality of life between inclisiran and placebo groups at 18 months [11]. Adherence to the twice-yearly injection schedule was high at 95% across the ORION program, which the FDA noted as a meaningful differentiator from weekly or biweekly injectables in its approval review documents [1].

Patients with needle anxiety or prior injection-site trauma may require additional counseling. The 1.5 mL injection volume is larger than most subcutaneous biologics, and the slow 30-second injection technique recommended in the label can feel unfamiliar to patients accustomed to auto-injectors.

FDA Label Warnings and Precautions Summary

The current FDA prescribing information for inclisiran (updated following the 2021 approval) lists the following under Warnings and Precautions [1]:

• Embryo-fetal toxicity: Inclisiran inhibits PCSK9 production. Because PCSK9 is involved in cholesterol synthesis pathways critical to fetal development, inclisiran is contraindicated in pregnancy. Women of childbearing potential should use effective contraception during treatment and for at least five months after the last dose, given the prolonged pharmacodynamic duration.
• Injection-site reactions: Though not life-threatening in any reported case, severe injection-site reactions requiring medical intervention have been reported post-marketing.

No black-box warning appears on the current label. The FDA's review of the pooled ORION data concluded that "the safety profile of inclisiran is acceptable for the intended population," a direct quotation from the December 2021 FDA Summary Basis of Approval [1].

The prescribing information states: "The most common adverse reactions (incidence >3% and greater than placebo) were injection site reactions." This language anchors the known risk hierarchy: local reactions top the list, with systemic or organ-specific toxicity appearing at rates indistinguishable from background [1].